Overview

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Canagliflozin
Hypoglycemic Agents